Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIG in Myasthenia Gravis Exacerbation
NCT02774239Phase 3Completed
- Sponsor
- University of Alberta
- Start
- Oct 2014
- Primary completion
- Oct 2022
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, single-blind, single-arm trial of polyvalent human immunoglobulin in myasthenia gravis (MG), sponsored by University of Alberta. Primary endpoint: Quantitative Myasthenia Gravis Score at Day 42. Started Oct 2014; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT02774239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02774239.